Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression.
Lishay ParhiTamar Alon-MaimonAsaf SolDeborah NejmanAmjad ShhadehTanya Fainsod-LeviOlga YajukBatya IsaacsonJawad AbedNaseem MaaloufAviram NissanJudith SandbankEinav Yehuda-ShnaidmanFalk PonathJörg VogelOfer MandelboimZvi GranotRavid StraussmanGilad BachrachPublished in: Nature communications (2020)
Fusobacterium nucleatum is an oral anaerobe recently found to be prevalent in human colorectal cancer (CRC) where it is associated with poor treatment outcome. In mice, hematogenous F. nucleatum can colonize CRC tissue using its lectin Fap2, which attaches to tumor-displayed Gal-GalNAc. Here, we show that Gal-GalNAc levels increase as human breast cancer progresses, and that occurrence of F. nucleatum gDNA in breast cancer samples correlates with high Gal-GalNAc levels. We demonstrate Fap2-dependent binding of the bacterium to breast cancer samples, which is inhibited by GalNAc. Intravascularly inoculated Fap2-expressing F. nucleatum ATCC 23726 specifically colonize mice mammary tumors, whereas Fap2-deficient bacteria are impaired in tumor colonization. Inoculation with F. nucleatum suppresses accumulation of tumor infiltrating T cells and promotes tumor growth and metastatic progression, the latter two of which can be counteracted by antibiotic treatment. Thus, targeting F. nucleatum or Fap2 might be beneficial during treatment of breast cancer.